Company intelligence
ALK Positive Lung Cancer UK
A registered lung cancer charity established by ALK-positive patients, their families and friends.
About ALK Positive Lung Cancer UK
ALK Positive Lung Cancer UK is a registered charity established by patients, their families and friends. ALK-positive lung cancer is a rare and relatively unknown form of lung cancer caused by the abnormal rearrangement of the anaplastic lymphoma kinase gene. Founded in 2018, our purpose is to provide support and advocacy and to improve the overall survival and quality of life of ALK-positive lung cancer patients across the United Kingdom. We are recognised by the National Institute for Health and Care Excellence (NICE) as an organisation to be consulted on new ALK-positive treatments.
Verified activity
Signals from ALK Positive Lung Cancer UK
2 published signals
Research & Knowledge
ALK Positive Lung Cancer UK announced that a new ALK+ lung cancer drug, ficonalkib, is being studied in a phase 2 trial at WCLC 2026 in Seoul.
Reported by ALK Positive Lung Cancer UK
Research & Knowledge
ALK Positive Lung Cancer UK published new research on resistance to targeted treatments in 590 people with oncogene-driven lung cancers, including 148 people with ALK+ lung cancer.
Reported by ALK Positive Lung Cancer UK